Company: CMND
Filing Date: 2025-11-17
Form Type: 424B5
Source: 0001213900-25-111233
Chunk: 7

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-17
Form: 424B5
Chunk 7
---
 I/IIa clinical trial. In addition, also in June 2025, we announced that the first patient
was enrolled and dosed in our Phase I/IIa clinical trial at Yale School of Medicine’s Department of Psychiatry. In July 2025, we
announced that we received IRB approval from TASMC for our Phase I/IIa clinical trial , and in August 2025, we announced that we received
IRB approval from Hadassah-University Medical Center. In July 2025, we announced initiation of the TASMC clinical site.

<div align='center'>S-1</div>

The CM-CMND-001 clinical trial
is designed to be a multinational, multi-center, double blind, Phase I/IIa single- and multiple-dose tolerability, safety and pharmacokinetic
study in healthy volunteers and AUD subjects. Upon completion of the Phase I/IIa studies, if successful, we will be required to conduct
additional clinical trials subject to securing additional financing.

About MEAI

MEAI is a synthetic molecule.
Its mechanism of action has been studied and published in the past in scientific papers. It was found to interact with the serotonergic
receptors 5-HT1A and 5-HT2B and the adrenergic receptors α2A, α2B and α2C receptors. The interaction with the 5HT2B
receptor was determined as non-agonist activity. Studies conducted in animals and humans have demonstrated the role of 5-HT1A receptors
in alcohol-drinking behavior. Several 5-HT1A receptor agonists have been tested in animal models to demonstrate the role of this receptor
in alcohol dependence. These preclinical studies suggest that 5-HT1A receptor agonists may play a role in reducing alcohol intake. In
addition, evidence suggests that α2-adrenergic receptor agonist signaling may play a role in mediating alcohol-drinking behavior
in both rodents and humans.

The literature shows that
5-HT1A receptors are associated with controlling craving behaviors across the board. This indicates that MEAI may have a wide range of
applications beyond AUD and binge drinking. Until today, only pre-clinical studies have been conducted with MEAI, including in-vitro and
in-vivo studies. The studies were conducted in the United States, China, France and Israel.

MEAI is a neuroplastogens
non-hallucinogenic molecule, exert